X0708 D/A LIVE 0001667699 Renibus Therapeutics, Inc. 181 GRAND AVE., SUITE 225 SOUTHLAKE TX TEXAS 76092 386-527-1071 DELAWARE None None Corporation true Carlos Guillem 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Director D. Jeffrey Keyser 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Executive Officer Director Henrik Rasmussen 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Director Bhupinder Singh 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Executive Officer Director Jamie Donadio 181 Grand Ave., Suite 225 Southlake TX TEXAS 76092 Executive Officer Pharmaceuticals Decline to Disclose 06b true 0001567619-23-007234 2023-05-25 true true true true false 0 Salem Partners LLC 43363 None None 11111 Santa Monica Blvd., Ste. 2250 Los Angeles CA CALIFORNIA 90025 GA GEORGIA TX TEXAS false 110895239 110895239 0 Amounts listed include amounts from certain converting SAFEs, which may have been previously reported on Form D, and certain warrants (see Item 15). The SAFEs converted into Series B-1 Preferred Stock at the initial closing of the transaction. false 59 0 148332 true Issuer paid placement agent cash fee of 1% of aggregate amount of proceeds from sale of Series B Preferred from 06/06/2025 to 06/17/2025 and issued placement agent warrants to purchase up to 96,971 shares of Common Stock (exercise price per share, $1.61). 0 false Renibus Therapeutics, Inc. /s/ D. Jeffrey Keyser D. Jeffrey Keyser Chief Executive Officer 2025-07-17